^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BI-3406 (SOS1 inhibitor) |
| Drug Class: | MEK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
Published date:
08/19/2020
Excerpt:
...a highly potent, selective and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1 thereby preventing the interaction with KRAS….Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors.
DOI:
10.1158/2159-8290.CD-20-0142
